about
Beta-blocker use and COPD mortality: a systematic review and meta-analysisPharmacogenomics in Pediatric Patients: Towards Personalized MedicineGenetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapyClinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin TherapyGenetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomicsUse of oseltamivir in childrenAn in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration.Identifying persons with treated asthma using administrative data via latent class modelling.Cases: Cocaine adulterant linked to neutropeniaFifty years of pediatric asthma in developed countries: how reliable are the basic data sources?Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.Risperidone and Risk of Gynecomastia in Young Men.Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.Genetic determinants of cocaine-associated agranulocytosis.Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials.Quantifying adverse drug events : are systematic reviews the answer?A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia.Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell linesHair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational studyClinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.Pharmacogenomics and adverse drug reactions in children.The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.Pharmacogenomics and active surveillance for serious adverse drug reactions in children.Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations.Pharmacogenomics of serious adverse drug reactions in pediatric oncology.Phenotype standardization for immune-mediated drug-induced skin injury.Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe.Cancer pharmacogenomics in children: research initiatives and progress to date.High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada.The emerging era of pharmacogenomics: current successes, future potential, and challenges.Use of pharmacogenomics in pediatric renal transplant recipients.Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery.Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study.The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis.
P50
Q27026866-C29BBACF-9441-46EB-922F-A0E1C3A4498FQ28071448-A09C8C04-6456-471A-841B-61C5FE5BD168Q28264131-78F1FEDF-E7B4-4796-8A97-EDE640E576ABQ28265249-691C30C4-D010-4408-9E78-197001EFEEDCQ28601852-1C7FB4FE-AD9B-42B0-BC11-C6C2ED5761EDQ30383447-211B3C4C-BEAA-46EC-99BC-F8E1F1F960F2Q30489261-C6607DE2-823B-428F-97EF-61737783573EQ31150803-7AC7692B-CC46-403D-827A-61E9EFC92F7BQ33575471-1A3E4822-BEC0-4D56-8171-09533E81F15FQ34014753-4EF7FA04-0C6F-40F6-89E7-FE8029D0D3CEQ34137741-4C4DF29E-F327-486D-BDD2-1A856B5DD2CAQ34408357-2E890D15-C7E1-4060-82A1-9A3F263845F9Q34490090-B4B9D34B-B5F7-4034-9745-6E0717CE3089Q34697234-0B8DFFAC-2130-439B-B8E5-01415C66EB4EQ34905699-532BF66D-9039-47CD-936B-97EE0219596EQ35662528-5A366B6F-AB4C-4E10-AD3D-2DA4032F06D7Q35709736-CF14A07A-1FCD-489B-BF98-0C03F47952B1Q35879011-6A989438-94CC-47CB-ABD4-D5334EBFCB40Q36004460-947D55B4-567E-4852-960C-64DA7F9BC837Q36195559-330D7127-9E3D-4E94-845D-CC49693F0063Q36345956-31114A7F-247D-4111-85F6-FE880D21E56FQ37113084-D20A9DCA-E4EC-414B-8059-0860D0761AEBQ37261320-424CC948-8096-4019-9B1C-DACACA350BF8Q37341208-94DFF265-AF0E-4B47-B496-F81A6D7B2D44Q37652392-2B717899-3975-4964-A740-177F84C4A000Q37719025-3CEBDEBE-A330-4DA3-8232-6D13EF72C4DCQ37767710-E9D70638-48D5-426D-9264-5AEB790D48CDQ37791154-D623F9F1-688C-41E9-98B8-17686F53C3BCQ37809965-8657C60A-6AFA-431F-B076-667AE6D41637Q37861998-0CEF4CC7-BDD9-4EA7-8920-FDFEC9E5E108Q37874437-78422654-AE78-4E25-B960-450A6D4B69DEQ37897564-87498CCE-F9DC-4BB8-825E-5DEE57860C31Q38093137-AD36FB42-7FA8-457C-97F4-A26CD78F0D27Q38096344-8FD82415-3A9B-4FE0-9512-3ABD8DF214E8Q38200683-9B56B9AE-0FE4-4B9F-8D95-D4391810EC94Q38367819-81A93D24-8C45-4F42-8D94-A80F831AF0FDQ38402203-C22BCEAA-FA13-43DA-A6BB-4BE66FDC3CA8Q38403997-2E0EFBFA-FA97-462F-BB91-CD3F8D458E61Q38406255-C5638C83-7AD4-4AE0-85E5-EC8F8982B2AEQ38422774-927CFE21-A4C5-4E7F-B923-1E59C26201CD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bruce C Carleton
@ast
Bruce C Carleton
@en
Bruce C Carleton
@es
Bruce C Carleton
@nl
Bruce C Carleton
@sl
type
label
Bruce C Carleton
@ast
Bruce C Carleton
@en
Bruce C Carleton
@es
Bruce C Carleton
@nl
Bruce C Carleton
@sl
altLabel
Bruce C. Carleton
@en
prefLabel
Bruce C Carleton
@ast
Bruce C Carleton
@en
Bruce C Carleton
@es
Bruce C Carleton
@nl
Bruce C Carleton
@sl
P108
P106
P108
P21
P31
P496
0000-0002-4485-4054